Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243165
Status:
UNKNOWN
Last Update Posted:
2009-12-07
First Post:
2005-10-20
Brief Title:
Lifemel Honey to Reduce Leucopenia During Chemotherapy
Sponsor:
Rambam Health Care Campus
Organization:
Rambam Health Care Campus
Study Overview
Official Title:
Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia
Status:
UNKNOWN
Status Verified Date:
2005-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC adriamycin- cyclophosphamide or CAF adriamycin- cyclophosphamide- 5- fluorouracil combinations These patients will receive every day one spoon of Lifemel honey or regular honey double blind- during the adjuvant chemotherapy Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None